These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 21138627)
1. [Correlation between the spontaneous clearance of HBV DNA and the levels of alanine aminotransferase in chronic hepatitis B]. Cui MF; Gao YF; Zhang WS; Wu N; Li N; Lü F; Su F Zhonghua Gan Zang Bing Za Zhi; 2010 Nov; 18(11):814-7. PubMed ID: 21138627 [TBL] [Abstract][Full Text] [Related]
2. [Analysis of spontaneous decline of HBV DNA in chronic hepatitis B patients in 12 weeks]. He H; Xu ZN; Cai DC; Nai N; Ling N; Zeng WQ; Shi XF; Zhao YR; Zhou Z; Zhang DZ Zhonghua Gan Zang Bing Za Zhi; 2009 Apr; 17(4):271-4. PubMed ID: 19403025 [TBL] [Abstract][Full Text] [Related]
3. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901 [TBL] [Abstract][Full Text] [Related]
4. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy. Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171 [TBL] [Abstract][Full Text] [Related]
5. [Quantitative detection of intrahepatic hepatitis B virus DNA in patients with chronic hepatitis B]. Lu H; Ma LX; Xu WS; Zhang HY; Yu LJ; Duan HY Zhonghua Gan Zang Bing Za Zhi; 2003 Mar; 11(3):173-5. PubMed ID: 12681068 [TBL] [Abstract][Full Text] [Related]
6. [Serum ALT and HBV DNA levels in patients with HBeAg-negative chronic hepatitis B]. Kim KH; Na IH; Cha JM; Cho YK; Park SY; Kim HP; Song CS; Heo J; Cho M Taehan Kan Hakhoe Chi; 2003 Dec; 9(4):284-92. PubMed ID: 14695695 [TBL] [Abstract][Full Text] [Related]
7. [Can HBsAg levels guide to differentiate inactive HBsAg carriers from HBeAg negative chronic B hepatitis?]. Sayan M; Mutlu B; Erdoğan S; Meriç M; Willke A Mikrobiyol Bul; 2007 Jan; 41(1):87-93. PubMed ID: 17427556 [TBL] [Abstract][Full Text] [Related]
8. [Relations between ALT level and count of HBV special CTL and non-specific CTL in patients with chronic hepatitis B]. Gu XB; Yang XJ; Wang D; Hua Z; Wu HY; Xu YQ; Lu ZH Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Oct; 23(5):343-5. PubMed ID: 20387481 [TBL] [Abstract][Full Text] [Related]
9. [A multicenter study of the effectiveness of interferon alpha-1b (Hapgen) in treating HBeAg positive chronic hepatitis B patients]. Jin R; Guo XH; Huang JF; Liu Z; Li HW; Wang ZB; Zhang B; Xie YM Zhonghua Gan Zang Bing Za Zhi; 2011 Jan; 19(1):25-8. PubMed ID: 21272454 [TBL] [Abstract][Full Text] [Related]
10. [Clinical significance of intrahepatic hepatitis B core antigen (+) in patients with chronic hepatitis B]. Pan HY; Zhang YL; Chen CR; Wang J; Li BR; Lu DR; Lou GQ; Shi JP Zhonghua Gan Zang Bing Za Zhi; 2007 Aug; 15(8):582-4. PubMed ID: 17711626 [TBL] [Abstract][Full Text] [Related]
11. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800 [TBL] [Abstract][Full Text] [Related]
12. e-antigen-negative chronic hepatitis B in Bangladesh. Ahmad N; Alam S; Mustafa G; Adnan AB; Baig RH; Khan M Hepatobiliary Pancreat Dis Int; 2008 Aug; 7(4):379-82. PubMed ID: 18693173 [TBL] [Abstract][Full Text] [Related]
13. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112 [TBL] [Abstract][Full Text] [Related]
14. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549 [TBL] [Abstract][Full Text] [Related]
15. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection. Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067 [TBL] [Abstract][Full Text] [Related]
16. [Study of the relapse of patients with chronic hepatitis B undergoing first and repeated recombinant interferon-alpha therapy during long-term follow up]. Liu DL; Luo KX; Feng XR; Fu QX; Hou JL Zhonghua Yi Xue Za Zhi; 2007 Jul; 87(26):1840-3. PubMed ID: 17922996 [TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of HBV DNA load in patients with chronic hepatitis B infection. Madan K; Batra Y; Jha JK; Kumar S; Kalra N; Paul SB; Singh R; Duttagupta S; Panda SK; Acharya SK Trop Gastroenterol; 2008; 29(2):84-90. PubMed ID: 18972767 [TBL] [Abstract][Full Text] [Related]
18. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Chan HL; Wang H; Niu J; Chim AM; Sung JJ Antivir Ther; 2007; 12(3):345-53. PubMed ID: 17591024 [TBL] [Abstract][Full Text] [Related]
19. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Chu CJ; Hussain M; Lok AS Hepatology; 2002 Dec; 36(6):1408-15. PubMed ID: 12447866 [TBL] [Abstract][Full Text] [Related]
20. Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan. Chien RN; Liaw YF Antivir Ther; 2006; 11(7):947-52. PubMed ID: 17302259 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]